KMT2A and cancer: Based on the significant requirement for the WRAD subcomplex for activity of all KMT2/MLL proteins and the emerging evidence that KMT2/MLL proteins likely play a role in tumor maintenance, evaluating the efficacy of targeting components of the WRAD subcomplex for the treatment of cancer could be highly efficacious.